---
title: "HIND.US (HIND.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/HIND.US/news.md"
symbol: "HIND.US"
name: "HIND.US"
parent: "https://longbridge.com/en/quote/HIND.US.md"
datetime: "2026-03-14T23:38:00.063Z"
locales:
  - [en](https://longbridge.com/en/quote/HIND.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/HIND.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/HIND.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/HIND.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/HIND.US/news.md)


# HIND.US (HIND.US) — Related News

### [Zydus Lifesciences Gets US FDA's Final Approval for Cevimeline Hydrochloride Capsules](https://longbridge.com/en/news/278987228.md)
*2026-03-13T05:16:26.000Z*
> Zydus Lifesciences Gets US FDA's Final Approval for Cevimeline Hydrochloride Capsules

### [Supriya Lifescience Publishes Postal Ballot Notice in Newspapers](https://longbridge.com/en/news/278783314.md)
*2026-03-11T21:53:24.000Z*
> Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

### [Zydus Lifesciences says successful clinical development of pembrolizumab biosimilar fyb206](https://longbridge.com/en/news/277174349.md)
*2026-02-27T09:35:53.000Z*
> Zydus Lifesciences says successful clinical development of pembrolizumab biosimilar fyb206

### [Vyome’s Livechain Acquires Humanyze to Expand AI HR Analytics](https://longbridge.com/en/news/276953703.md)
*2026-02-25T22:55:13.000Z*
> Vyome Holdings' subsidiary, Livechain, has acquired Humanyze for $5.77 million in an all-stock deal, issuing 211.2 milli

### [Zydus: From Generics to Innovation Powerhouse](https://longbridge.com/en/news/276109706.md)
*2026-02-17T09:41:00.000Z*
> Zydus Lifesciences has shifted from a generics manufacturer to an innovation-driven pharmaceutical company, focusing on 

### [Vyome Holdings, Inc. Reports Positive Phase 2 Results for VT-1953](https://longbridge.com/en/news/275890596.md)
*2026-02-13T11:13:00.000Z*
> Vyome Holdings, Inc. reported positive Phase 2 results for VT-1953 on February 12, 2026. The treatment for malignant fun

### [India's Zydus, US unit settle Mirabegron patent dispute with $120 million payment](https://longbridge.com/en/news/275693014.md)
*2026-02-12T03:12:21.000Z*
### [Vyome Files For VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over The Next 6 Months](https://longbridge.com/en/news/275600818.md)
*2026-02-11T12:04:09.000Z*
### [Insights Ahead: Edwards Lifesciences's Quarterly Earnings](https://longbridge.com/en/news/275342635.md)
*2026-02-09T16:01:44.000Z*
> Edwards Lifesciences (NYSE:EW) is set to announce its quarterly earnings on February 10, 2026, with analysts estimating